alere selling 25% of bbi, page-34

This may be of interest to some

Roche snags diagnostics outfit IQuum in $450M deal

April 7 2014

Roche is beefing up its point-of-care molecular diagnostics offerings, signing a deal to acquire IQuum for 275m up front and 175m in milestone payments.

Privately held IQuums offerings are the liat Analyzer and the Liat Influenza A/b assay. The Analyzer enables molecular diagnostics test to be performed by minimally trained employees in point of care settings in 20-60 minutes, according to IQuum website, and the A and B Assay detects and discriminates between Influenza A and B. Once the transaction is complete Iquum will Roches molecular diagnostics division.

Both products are marked CE and FDA cleared and utilize IQuums Laboratory in tube (Liat) System, which the company says enables ease of use while preserving specificity and sensitivity.

WOW $450m just for that alone and still takes up to 1hr to get results.

A good chance roche is looking at M&G